Search Results - "Mcewan, Philip"

Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy by Gordon, Jason P., Evans, Marc, Puelles, Jorge, McEwan, Philip C.

“…Introduction The objectives of this study were to (a) assess the factors associated with weight gain in a population of type 2 diabetes patients escalating…”
Get full text

Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha by Wechowski, Jaroslaw, M.D., Ph.D, Connolly, Mark, M.Sc, Schneider, Dirk, M.D, McEwan, Philip, Ph.D, Kennedy, Richard, M.D

“…Objective To assess the cost-effectiveness of two gonadotropin treatments that are available in the United Kingdom in light of limited public funding and the…”
Get full text

Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection by McEwan, Philip, Ward, Thomas, Chen, Chien-Jen, Lee, Mei-Hsuan, Yang, Hwai-I, Kim, Ray, L’Italien, Gilbert, Yuan, Yong

“…Hepatitis C virus (HCV) infection is the leading cause of liver disease, and Taiwan has among the highest prevalence of HCV infection in the general population…”
Get full text

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom by Woehl, Anette, Evans, Mark, Tetlow, Anthony P, McEwan, Philip

“…Exenatide belongs to a new therapeutic class in the treatment of diabetes (incretin mimetics), allowing glucose-dependent glycaemic control in type 2 diabetes…”
Get full text

1059-P: Excess Body Weight Contributes to an 8.3 Year Premature Health Economic Aging Equivalent to an Additional Annual Healthcare Expenditure of $306B-Results of a U.S. Population Study by Evans, Marc, Padgett, Thomas, Mcewan, Philip

“…Introduction: Premature ageing is a recognized feature of chronic disease. As healthcare expenditure increases with age, the concept of health economic (HE)…”
Get full text

1041-P: Assessing the Value of Managing Diabetic Kidney Disease from a U.S. Health Care Perspective by Mcewan, Philip, Padgett, Thomas, Evans, Marc

“…Introduction: The management of diabetic kidney disease (DKD) is associated with considerable resource utilization. The objective of this study was to estimate…”
Get full text

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study by Sharplin, Peter, Gordon, Jason, Peters, John R, Tetlow, Anthony P, Longman, Andrea J, McEwan, Philip

“…Insulin glargine (glargine) and insulin NPH (NPH) are two basal insulin treatments. This study investigated the effect on glycaemic control of switching from a…”
Get full text

Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis by Sharplin, Peter, Gordon, Jason, Peters, John R, Tetlow, Anthony P, Longman, Andrea J, McEwan, Philip

“…Insulin glargine (glargine) and premixed insulins (premix) are alternative insulin treatments. This analysis evaluated glycaemic control in 528 patients with…”
Get full text

990-P: Estimating the National Costs of T2DM in the UK within the Context of Contemporary Guidelines by MCEWAN, PHILIP, FOOS, VOLKER, MARTIN, REBECCA, CHEN, JIELING

“…Background: The updated National Institute for Health and Care Excellence (NICE) type 2 diabetes (T2D) guidelines extend the recommendation of SGLT2 inhibitors…”
Get full text

1040-P: The Value of the Guideline-Recommended Management of Type 2 Diabetes-A Novel Population-Level System Dynamics Approach by Mcewan, Philip, Padgett, Thomas, Goulden, Scott R, Chubb, Barrie, Mansinho, Joana N, Ren, Hongye

“…Introduction and Objectives: Current clinical guidelines advocate a holistic approach (HA) to type 2 diabetes (T2D) management based on glucose control,…”
Get full text

Hyperkalaemia Risk and Mortality in Patients with Diabetes: PO0968 by McEwan, Philip, Hurst, Michael A., Hoskin, Louise, Tafesse, Eskinder, Badora, Karolina, Sugrue, Daniel, James, Glen

Get full text

The Relationship Between Comorbidities and Hyperkalaemia in Patients with CKD: PO1448 by Tafesse, Eskinder, James, Glen, Sugrue, Daniel, Hurst, Michael A., Hoskin, Louise, Badora, Karolina, McEwan, Philip

Get full text

Relationships Between CKD Duration, Serum Potassium Level, and Adverse Outcomes: PO1450 by Tafesse, Eskinder, James, Glen, Hurst, Michael A., Hoskin, Louise, Badora, Karolina, Sugrue, Daniel, McEwan, Philip

Get full text

Translating the Findings of DAPA-CKD to Reductions in Healthcare Resource Utilization and Costs: SA-PO887 by McEwan, Philip, Miller, Ryan, Sanchez, Juan Jose Garcia, Barone, Salvatore, Nolan, Stephen, Jha, Vivekanand, Correa-Rotter, Ricardo, Chernin, Gil, De Nicola, Luca

Get full text

Modelling the Clinical and Economic Burden of Anaemia in Patients with CKD: PO0275 by Darlington, Oliver T., Booth, David, Gabb, Peter D., Sanon, Myrlene, Michalopoulos, Efstathios N., Farag, Youssef M., Wang, Xinyu, McEwan, Philip

Get full text

The Impact of Decline in Renal Function on the Clinical and Economic Burden of CKD: An Application of the DAPA-CKD Cost-Effectiveness Model: PO0589 by McEwan, Philip, Sanchez, Juan Jose Garcia, Bergenheim, Klas, Darlington, Oliver T., Wheeler, David C., Heerspink, Hiddo J. L

Get full text

15-OR: Renal Outcomes from the DECLARE-TIMI 58 Trial: Quantifying the Health-Care Implications by MCEWAN, PHILIP, KARTMAN, BERNT, BENNETT, HAYLEY, EDMONDS, CHRISTOPHER, GAUSE-NILSSON, INGRID ANNA

“…Chronic kidney disease (CKD) and end stage renal disease (ESRD) pose a significant global health burden. Approximately 40% of people with type 2 diabetes…”
Get full text

1213-P: Assessing the Performance of Cardiovascular Risk Equations in the DECLARE-TIMI 58 Population by MCEWAN, PHILIP, FOOS, VOLKER, BENNETT, HAYLEY, KARTMAN, BERNT, EDMONDS, CHRISTOPHER, GAUSE-NILSSON, INGRID ANNA

“…Sodium-glucose co-transporter inhibitors have demonstrated reduced incidence of cardiovascular (CV) events, which cannot be fully explained by effects on…”
Get full text

1269-P: Assessing the Performance of the UKPDS 82 Risk Equations to Predict Cardiovascular Events in the DECLARE-TIMI 58 Trial Population by MCEWAN, PHILIP, FOOS, VOLKER, BENNETT, HAYLEY, KARTMAN, BERNT, EDMONDS, CHRISTOPHER, GAUSE-NILSSON, INGRID ANNA

“…Risk equations (RE) from the UK Prospective Diabetes Study (UKPDS) remain the most commonly used within economic models of type 2 diabetes mellitus (T2DM)…”
Get full text

Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model by McEwan, Philip, Ward, Thomas, Bennett, Hayley, Bergenheim, Klas

“…For end-users of diabetes models that include UKPDS 82 risk equations, an important question is how well these new equations perform. Consequently, the…”
Get full text